Enlivex Therapeutics (NASDAQ:ENLV) Raised to “Hold” at Wall Street Zen

Enlivex Therapeutics (NASDAQ:ENLV) was upgraded by Wall Street Zen from a “strong sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other analysts have also recently commented on ENLV. D. Boral Capital reaffirmed a “hold” rating on shares of Enlivex Therapeutics in a research report on Monday, November 24th. HC Wainwright raised their target price on Enlivex Therapeutics from $7.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday. D Boral Capital lowered Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Enlivex Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $13.00.

Enlivex Therapeutics Stock Up 0.7%

Shares of NASDAQ:ENLV opened at $0.94 on Friday. The firm has a 50 day moving average of $0.91 and a 200 day moving average of $1.07. Enlivex Therapeutics has a 52 week low of $0.66 and a 52 week high of $2.10. The company has a market capitalization of $223.14 million, a price-to-earnings ratio of -1.71 and a beta of 1.52.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. On average, sell-side analysts expect that Enlivex Therapeutics will post -0.7 EPS for the current year.

Institutional Trading of Enlivex Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC grew its position in Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after buying an additional 67,886 shares during the last quarter. Citizens Financial Group Inc. RI acquired a new stake in Enlivex Therapeutics during the 3rd quarter worth approximately $241,000. Finally, Susquehanna International Group LLP purchased a new position in shares of Enlivex Therapeutics in the 3rd quarter valued at $57,000. 1.02% of the stock is owned by institutional investors and hedge funds.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.